REX-7117 / Recludix Pharma - LARVOL DELTA

REX-7117 is a highly potent and selective oral STAT3 inhibitor that has demonstrated potential efficacy and safety differentiation versus JAK/TYK2 targeting in preclinical models of psoriasis (PsoriasisG2C 2024) - "In dogs and mice, REX-7117 achieves deep, durable, and selective STAT3 inhibition at clinically relevant oral doses and exhibits comparable efficacy to an IL-17 antibody in rodent models of plaque psoriasis. Selective STAT3 inhibition has the potential to combine the efficacy of clinically validated biologics with the convenience of oral administration, while avoiding known safety concerns observed with the broader activity of JAK and TYK2 inhibitors."

Preclinical • Anemia • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Thrombocytopenia • IL17A • IL23A • IL6 • JAK1 • JAK2 • TYK2

REX-7117 Is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis (ACR Convergence 2024) - "Selective STAT3 inhibition brings the promise of combining the efficacy of clinically validated biologics with the convenience of oral administration, while potentially avoiding known safety concerns observed with the broader activity of JAK/TYK2 inhibitors."

Preclinical • Anemia • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Thrombocytopenia • IL17A • IL6 • TYK2

Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit (Yahoo Finance) - "Recludix Pharma...announced that in a presentation given today at the 7th Annual Dermatology Drug Development Summit....Recludix’s senior vice president of biology, Paul Smith, Ph.D., reviewed the challenges associated with inhibition of the JAK/STAT pathway through TYK2 and JAK inhibitors and presented preclinical data with Recludix’s STAT3 inhibitor REX-7117, which potently and selectively targets the STAT3 Src Homology 2 (SH2) domain....In a translational Th17 preclinical model of psoriasis, once daily REX-7117 (300 mg/kg) was superior to a clinically-relevant dose of deucravacitinib (1 mg/kg). Moreover, twice daily REX-7117 (300 mg/kg) was comparable to deucravacitinib at a supra-clinical dose (30 mg/kg), reinforcing the rationale of STAT3 targeting as a potential disease-modifying opportunity."

Preclinical • Immunology • Psoriasis